Replies to post #161710 on Biotech Values

[mcbio]

ACHN

Kishbauch was 63, which is not that old for a CEO. Under the circumstances, it seems reasonable to infer that ACHN’s incessant predictions of a major HCV partnership were exaggerated.

First the CMO (departure, not retirement) and now the CEO. I find it hard to give any consideration to a position in ACHN again.